Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flibanserin in Breast Cancer Survivors on Tamoxifen and Aromatase Inhibitors
NCT03707340Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2018
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of flibanserin in hypoactive sexual desire disorder (HSDD), sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2018; status: active, not recruiting.
02
Drugs
flibanserin
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT03707340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707340.